Atópiás dermatitisz (ekcéma): vizsgálatok itt: Kína
57 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Where
- Beijing, Changsha, Hangzhou, Nanchang, Shanghai, Shenzhen
- Életkor
- 2 év to 11 év
- People
- 450 worldwide
- Run by
- Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00 - 2. fázisTaking peopleA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
- Where
- Beijing, Fuzhou, Guangzhou, Shanghai
- Életkor
- 18 év to 64 év
- People
- 165 worldwide
- Run by
- Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00 - 1. fázisTaking peopleA Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
- Where
- Beijing, Fuzhou, Hangzhou, Jinan, Nanchang, Shanghai
- Életkor
- 18 év to 65 év
- People
- 84 worldwide
- Run by
- Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07235384 - No phaseTaking peopleThis Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Where
- Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai, Shenzhen, Xi’an
- Életkor
- 12 év and over
- People
- 1000 worldwide
- Run by
- Sanofi
See details and how to joinNCT07290803 - 2. fázisTaking peoplePhase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 160
- Run by
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT07895615 - 3. fázisTaking peopleRandomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 12 év and over
- People
- 240
- Run by
- Galderma R&D
See details and how to joinNCT07762833 - 3. fázisTaking peopleA Phase III Study of GS101 Injection to Dupixent®
- Where
- Shenyang
- Életkor
- 18 év to 75 év
- People
- 572
- Run by
- Jiangsu Genscend Biopharmaceutical Co., Ltd
See details and how to joinNCT07386743 - 3. fázisTaking peopleA Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 520
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07754786 - 3. fázisTaking peopleEvaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
- Where
- Beijing, Changsha, Guangzhou, Hangzhou
- Életkor
- 2 év to 11 év
- People
- 246
- Run by
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07767253 - 1. fázisTaking peoplePhase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Shanghai
- Életkor
- 18 hónap to 65 év
- People
- 84
- Run by
- QuantX Biosciences, Inc.
See details and how to joinNCT07800104 - 2. fázisTaking peoplePlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Where
- Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Shanghai, Shantou
- Életkor
- 18 év to 100 év
- People
- 224 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00 - 3. fázisTaking peopleA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- Where
- Beijing, Changsha, Hangzhou, Nanchang, Shanghai, Shenzhen
- Életkor
- 6 év to 11 év
- People
- 150 worldwide
- Run by
- Pfizer
See details and how to joinNCT06807268 · EU 2023-509121-51-00 - 3. fázisTaking peopleA Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
- Where
- Shanghai, Shenyang
- Életkor
- 12 év to 17 év
- People
- 201
- Run by
- Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07309055 - 1. fázisNot yet taking people in KínaA Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év to 70 év
- People
- 68
- Run by
- Helixon Biotechnology (Suzhou) Co., Ltd
See details and how to joinNCT07801612 - 1/2. fázisTaking peopleA Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 24
- Run by
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT06931990 - 3. fázisTaking peopleEvaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 480
- Run by
- Shanghai Longwood Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07370909 - 2/3. fázisNot yet taking people in KínaA Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 390
- Run by
- Hangzhou Highlightll Pharmaceutical Co., Ltd
See details and how to joinNCT07784816 - 1/2. fázisNot yet taking people in KínaStudy of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év to 70 év
- People
- 67
- Run by
- Helixon Biotechnology (Suzhou) Co., Ltd
See details and how to joinNCT07782476 - 3. fázisTaking peoplePhase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 480
- Run by
- Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT06723080 - 1. fázisTaking peopleA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
- Where
- Beijing, Changsha, Guangzhou, Hefei, Jinan, Nanchang, Shanghai, Wuhu, Wuxi, Zhenjiang
- Életkor
- 18 év to 65 év
- People
- 99
- Run by
- Bambusa Therapeutics
See details and how to joinNCT07239947 - 1. fázisTaking peopleA Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
- Where
- Shanghai
- Életkor
- 18 év to 45 év
- People
- 96
- Run by
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07693738 - 3. fázisTaking peoplePhase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
- Where
- Nanjing
- Életkor
- 12 év and over
- People
- 360
- Run by
- Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT07592585 - 2. fázisTaking peopleA Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 120
- Run by
- Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT07598383 - 2. fázisNot yet taking people in KínaThe Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 44
- Run by
- RenJi Hospital
See details and how to joinNCT07678645 - 1/2. fázisTaking peopleHL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
- Where
- Hangzhou
- Életkor
- 18 év to 75 év
- People
- 156
- Run by
- Hangzhou Highlightll Pharmaceutical Co., Ltd
See details and how to joinNCT07629778